A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.
Mohammad Mokhber: Who is Iran’s acting president?
WhatsApp has made a subtle change that has left users FURIOUS
Indian police kill 29 suspected Maoist rebels in a gunbattle in a central state
Coal miners are getting new protections from silica dust linked to black lung disease
Yu Darvish extends scoreless innings streak to 25 in Padres' 9
Cardi B, Queen Latifah and The Roots to headline the BET Experience concerts in Los Angeles
The Sky added plenty of star power in the WNBA draft with Kamilla Cardoso and Angel Reese
The 15 revolutionary tiny tweaks that can turbocharge your health
Celebrity birthdays for the week of May 26
US files 2nd labor complaint after Mexico refuses to act on union
Devout Christian doctor, 68, who punched dementia
Traveler issues severe warning to any 'morning people' who want to visit Argentina